Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Capital Expenditures (2016 - 2026)

Sunshine Biopharma filings provide 10 years of Capital Expenditures readings, the most recent being -$1039.0 for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 101.01% to -$1039.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $174491.0, a 89.47% decrease, with the full-year FY2025 number at $174491.0, down 89.47% from a year prior.
  • Capital Expenditures hit -$1039.0 in Q4 2025 for Sunshine Biopharma, down from $8040.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $974513.0 in Q2 2024 to a low of -$382363.0 in Q4 2023.
  • Median Capital Expenditures over the past 4 years was $62937.0 (2024), compared with a mean of $150254.5.
  • Biggest five-year swings in Capital Expenditures: plummeted 297.11% in 2023 and later surged 5266.46% in 2024.
  • Sunshine Biopharma's Capital Expenditures stood at $193982.0 in 2022, then plummeted by 297.11% to -$382363.0 in 2023, then soared by 126.83% to $102600.0 in 2024, then plummeted by 101.01% to -$1039.0 in 2025.
  • The last three reported values for Capital Expenditures were -$1039.0 (Q4 2025), $8040.0 (Q3 2025), and $160000.0 (Q2 2025) per Business Quant data.